Overview

A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial

Status:
Recruiting

Trial end date:
2025-05-01

Target enrollment:

Participant gender:

Summary

This randomized, phase 2 study will investigate the use of the Signatera ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer. The aim of this study will be to measure and compare the overall survival, progression-free survival, and best overall response while on study of patients whose treatment has been guided by these two approaches.

Phase:

Phase 2

Details

Lead Sponsor:

University of Florida

Collaborator:

Natera, Inc.